title: Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome".
authors.affiliation: Melanoma Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.
authors.forename: Lavinia
authors.initials: L
authors.lastname: Spain
authors.affiliation: Melanoma Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.
authors.forename: James
authors.initials: J
authors.lastname: Larkin
authors.affiliation: Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035, Barcelona, Spain. jmartinliberal@gmail.com.
authors.forename: Juan
authors.initials: J
authors.lastname: Martin-Liberal
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D061385:Insulins
chemical_list: D000911:Antibodies, Monoclonal; D061385:Insulins